Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 75Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Myeloproliferative Disorders 5Hematologic Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neoplasms 3Hematologic Diseases 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 16fludarabine 9Mycophenolic Acid 8Cytarabine 8venetoclax 7Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6Tacrolimus 5Cyclosporine 5ruxolitinib 4ponatinib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Etoposide 4Daunorubicin 4blinatumomab 3asciminib 3Vincristine 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Dexamethasone 3revumenib 2pegfilgrastim 2nilotinib 2ibrutinib 2Mesna 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × Azacitidine × 90 days × Clear all
NCT07007312 2026-06-03

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology, Inc.

Phase 3 Recruiting
1,300 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡